Mirabegron

Mirabegron is an approved prescription drug, not a research chemical. Astellas Pharma developed it as YM-178 and it was approved by the FDA in 2012 under the brand name Myrbetriq for overactive bladder, with European approval as Betmiga; the US label now also covers neurogenic detrusor overactivity in children aged three and older. It works by activating the beta-3 adrenergic receptor, which relaxes the bladder detrusor muscle.

The reason it appears on the research chemical market has nothing to do with bladders. Beta-3 receptors are also the main adrenergic receptors on rodent brown fat, and for decades beta-3 agonists were the leading candidate for a drug that would burn calories by turning on brown adipose tissue. Mirabegron was the first beta-3 agonist available in a form that could test that idea in people.

The first test worked. In twelve healthy men, a single oral dose increased brown fat metabolic activity measured by FDG PET-CT in every subject and raised resting metabolic rate by 203 kcal per day, about 13 percent (PMID: 25565203). A four-week open-label study in 14 healthy women found higher brown fat activity and resting energy expenditure with no change in body weight or composition, alongside higher HDL cholesterol, apolipoprotein A-I, adiponectin and improved insulin sensitivity on an intravenous glucose tolerance test (PMID: 31961826).

The complication is dose and receptor selectivity. A Canadian group showed that human brown adipocyte thermogenesis is actually driven by the beta-2 receptor, not beta-3, and that mirabegron only raised brown fat thermogenesis when taken at the maximum allowable dose, at which point it also bound beta-1 and beta-2 receptors, producing cardiovascular effects and white fat lipolysis (PMID: 32755608). A meta-analysis of six human studies found increased brown fat activity, resting energy expenditure, body temperature and free fatty acids, but also increased heart rate, diastolic blood pressure and insulin, with no change in brown fat volume or blood glucose (PMID: 38159219).

Pharmacology is well characterized because it is a licensed drug. Plasma concentrations peak at three to five hours and decline with a terminal half-life of roughly 32 to 60 hours across two phase 1 studies; exposure is about 40 percent higher in women than men, and steady state is reached within a week (PMID: 23063375). Absorption, metabolism and excretion have been mapped with radiolabeled drug (PMID: 22269146).

Anyone taking mirabegron for metabolic reasons is using an approved drug off-label at or near its ceiling dose, where the cardiovascular effects are real and measured. That is a different risk profile from its licensed bladder use, and it needs a prescriber, not a supplier.

Mirabegron is available in capsule form.

Compare prices, payment methods, shipping, and COA scores across 1 vendor.

1 of the vendors BodyHackGuide tracks list Mirabegron (1 listing). Among BodyHackGuide's Mirabegron listings recorded as in stock with a milligram count, the lowest price per milligram is $0.033/mg at Disguised Alpha and the median is $0.033/mg. The Mirabegron prices on BodyHackGuide are vendors' listed prices as BodyHackGuide last recorded them, not transactions; the most recent recorded change to a Mirabegron listing is dated 7 September 2026.

BodyHackGuide holds 3 third-party certificate records for Mirabegron, from . No editor has read any of BodyHackGuide's 3 certificate records for Mirabegron. The laboratory named on BodyHackGuide's Mirabegron certificate records is Freedom Diagnostics Testing, and the newest test date on them is 24 September 2026. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor and links to each record that has its own page.